This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
Read the original research
Reasons for Discontinuation of Obesity Pharmacotherapy With Semaglutide or Tirzepatide in Clinical Practice.
Obesity (Silver Spring, Md.), 33(12), 2296-2303
Citation
Gasoyan, Hamlet; Butsch, W Scott; Casacchia, Nicholas J; Schulte, Rebecca; Criswell, Victoria; Fox, Jacqueline; Renner, Holly; Le, Phuc; Alpert, Jordan; Rothberg, Michael B. (2025). Reasons for Discontinuation of Obesity Pharmacotherapy With Semaglutide or Tirzepatide in Clinical Practice.. Obesity (Silver Spring, Md.), 33(12), 2296-2303. https://doi.org/10.1002/oby.70058